These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 761184)

  • 21. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in mitochondrial and microsomal electron transport as affected by o,p'-dichlorodiphenyldichloroethane].
    Komissarenko VP; Mikosha AS; Chelnakova IS
    Ukr Biokhim Zh (1978); 1981; 53(6):74-7. PubMed ID: 6798728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenal proteins bound by a reactive intermediate of mitotane.
    Cai W; Counsell RE; Schteingart DE; Sinsheimer JE; Vaz AD; Wotring LL
    Cancer Chemother Pharmacol; 1997; 39(6):537-40. PubMed ID: 9118466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.
    Schteingart DE; Sinsheimer JE; Counsell RE; Abrams GD; McClellan N; Djanegara T; Hines J; Ruangwises N; Benitez R; Wotring LL
    Cancer Chemother Pharmacol; 1993; 31(6):459-66. PubMed ID: 8453685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of single and repeated in vitro exposure of ovarian follicles to o,p'-DDT and p,p'-DDT and their metabolites.
    Wójtowicz AK; Gregoraszczuk EL; Ptak A; Falandysz J
    Pol J Pharmacol; 2004; 56(4):465-72. PubMed ID: 15520502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitotane (1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane) metabolism in perfusion studies with dog adrenal glands.
    Sinsheimer JE; Freeman CJ
    Drug Metab Dispos; 1987; 15(2):267-9. PubMed ID: 2882989
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
    Feldman EC; Nelson RW; Feldman MS; Farver TB
    J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitotane for adrenocortical carcinoma treatment.
    Hahner S; Fassnacht M
    Curr Opin Investig Drugs; 2005 Apr; 6(4):386-94. PubMed ID: 15898346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mitotane on pituitary corticotrophs in clinically normal dogs.
    Taoda T; Hara Y; Takekoshi S; Itoh J; Teramoto A; Osamura RY; Tagawa M
    Am J Vet Res; 2006 Aug; 67(8):1385-94. PubMed ID: 16881851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Does Op'DDD possess an antimitotic action? Remarks apropos of its use in the treatment of adrenal adenocarcinomas].
    Bricaire H; Luton JP
    Nouv Presse Med; 1977 Nov; 6(39):3650. PubMed ID: 607185
    [No Abstract]   [Full Text] [Related]  

  • 32. [Chloditan-induced changes in lipid peroxidation in the adrenals of dogs and guinea pigs].
    Chelnakova IS; Tron'ko ND; Mikosha AS
    Biull Eksp Biol Med; 1989 Feb; 107(2):171-4. PubMed ID: 2923972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with o,p'-DDD (mitotane) decreased cytochrome P-450, heme, and microsomal protein content in the dog adrenal cortex in vivo.
    Martz F; Straw JA
    Res Commun Chem Pathol Pharmacol; 1976 Jan; 13(1):83-92. PubMed ID: 1257603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fine structural and biochemical effects of aminoglutethimide and o,p'-DDD on rat adrenocortical carcinoma 494 and adrenals.
    Moore RN; Penney DP; Averill KT
    Anat Rec; 1980 Sep; 198(1):113-24. PubMed ID: 7457928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.
    Boven E; Vermorken JB; van Slooten H; Pinedo HM
    Cancer; 1984 Jan; 53(1):26-9. PubMed ID: 6360329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding mitotane mode of action.
    Waszut U; Szyszka P; Dworakowska D
    J Physiol Pharmacol; 2017 Feb; 68(1):13-26. PubMed ID: 28456766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of chloditan on the changes of activity of glutathione transferase, glutathione reductase and glutathione content in the adrenal glands and liver in rats].
    Zorich PA; Tronko ND; Mikosha AS
    Fiziol Zh (1994); 1994; 40(1):86-90. PubMed ID: 7713231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Properties of adrenocortical isocitrate dehydrogenase].
    Mikosha AS; Monissarenko VP; Bychkovskaia LA
    Vopr Med Khim; 1981; 27(6):736-9. PubMed ID: 7336646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy.
    Ostuni JA; Roginsky MS
    Arch Intern Med; 1975 Sep; 135(9):1257-8. PubMed ID: 1164127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
    Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
    Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.